[Experiences with niflumic acid in inflammatory glomerulopathies].
Thirty patients with histologically ascertained blomerulonephritis and proteinuria were treated over an average period of 4 months with 750 mg/die 2-m-trigluoromethylanilino-nicotinic acid (niflumic acid, Actol). The following was shown: 1. In 73% of the cases the proteinuria diminished. 2. Kidney function remained unchanged, that is, it worsened only in such cases in which there was already limited functioning. 3. In case of initially increased values the secretion of fibrinogen degradation products diminished in 70% of the cases. 4. When the medication was stopped, its effects vanished. Niflumic acid shows to be an effective drug in the treatment of the nephrotic syndrome and the number of complications is smaller due to the improved condition of protein metabolism. Therefore, this form of treatment, in certain ways, influences the prognosis of the disease.
D003864:Depression, Chemical; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D005921:Glomerulonephritis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009404:Nephrotic Syndrome / Q000188:drug therapy; D009539:Nicotinic Acids / Q000627:therapeutic use*; D009544:Niflumic Acid / Q000627:therapeutic use*; D011507:Proteinuria / Q000188:drug therapy*
D009539:Nicotinic Acids; D009544:Niflumic Acid; D005340:Fibrinogen
Erfahrungen mit Nifluminsäure bei entzündlichen glomerulären Erkrankungen